Jump to content

Lenalidomide

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Boghog (talk | contribs) at 05:43, 9 August 2024 (consistent citation formatting). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Lenalidomide
Clinical data
Pronunciation/ˌlɛnəˈlɪdoʊmaɪd/
Trade namesRevlimid, Linamide, others
AHFS/Drugs.comMonograph
MedlinePlusa608001
License data
Pregnancy
category
  • AU: X (High risk)[1]
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityUndetermined
Protein binding30%
MetabolismUndetermined
Elimination half-life3 hours
ExcretionKidney (67% unchanged)
Identifiers
  • (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.218.924 Edit this at Wikidata
Chemical and physical data
FormulaC13H13N3O3
Molar mass259.265 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C1NC(=O)CCC1N3C(=O)c2cccc(c2C3)N
  • InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) checkY
  • Key:GOTYRUGSSMKFNF-UHFFFAOYSA-N checkY
  (verify)

Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS).[8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone.[8] It is taken by mouth.[8]

Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping.[8] Severe side effects include low blood platelets, low white blood cells, and blood clots.[8] The dose may need to be adjusted in people with kidney problems.[8] Lenalidomide is closely related to thalidomide, which is known to cause severe birth defects, so its use during pregnancy is very likely to harm the fetus.[8]

Lenalidomide belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs) or Cereblon E3 ligase modulators, which includes thalidomide and its analogs.[9] In lymphocytes, these drugs target an E3 ubiquitin ligase and change its specificity to include new targets.[9] This results in the rapid degradation of several disease-related proteins including IKZF1, IKZF3, and CSNK1A1.[9]

Lenalidomide was approved for medical use in the United States in 2005.[8] It is on the World Health Organization's List of Essential Medicines.[10]

Medical uses

[edit]

Multiple myeloma

[edit]

Lenalidomide is used to treat multiple myeloma.[11] It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, tumor-secreted cytokines, and tumor proliferation through induction of apoptosis.[12][13][14]

Lenalidomide is effective at inducing a complete or "very good partial" response and improves progression-free survival. Adverse events more common in people receiving lenalidomide for myeloma include neutropenia, deep vein thrombosis, infections, and an increased risk of other hematological malignancies.[15] The risk of second primary hematological malignancies does not outweigh the benefit of using lenalidomide in relapsed or refractory multiple myeloma.[16] It may be more difficult to mobilize stem cells for autograft in people who have received lenalidomide.[12]

In 2006, lenalidomide received US Food and Drug Administration (FDA) approval for use in combination with dexamethasone in people with multiple myeloma who have received at least one prior therapy.[17] In 2017, the FDA approved lenalidomide as standalone maintenance therapy (without dexamethasone) for people with multiple myeloma following autologous stem cell transplant.[18]

In 2009, The National Institute for Health and Clinical Excellence issued a final appraisal determination approving lenalidomide in combination with dexamethasone as an option to treat people with multiple myeloma who have received two or more prior therapies in England and Wales.[19]

The use of lenalidomide combined with other drugs was evaluated. It was seen that the drug combinations of lenalidomide plus dexamethasone and continuous bortezomib plus lenalidomide plus dexamethasone probably result in an increase of the overall survival.[20]

Myelodysplastic syndromes

[edit]

Lenalidomide was approved by the FDA in December 2005, for people with low- or intermediate-1-risk myelodysplastic syndromes who have chromosome 5q deletion syndrome (5q- syndrome) with or without additional cytogenetic abnormalities.[21][22][23] It was approved on 17 June 2013 by the European Medicines Agency for use in patients with low- or intermediate-1-risk myelodysplastic syndromes who have 5q- deletion syndrome but no other cytogenetic abnormalities and are dependent on red blood cell transfusions, for whom other treatment options have been found to be insufficient or inadequate.[24]

Mantle cell lymphoma

[edit]

Lenalidomide is approved by FDA as a specialty drug requiring a specialty pharmacy distribution for mantle cell lymphoma in people whose disease has relapsed or progressed after at least two prior therapies, one of which must have included the medicine bortezomib.[6]

AL amyloidosis

[edit]

Although not specifically approved by the FDA for use in treating AL amyloidosis, lenalidomide is sometimes used in the treatment of that condition, often in combination with dexamethasone.[25]

Adverse effects

[edit]

In addition to embryo-fetal toxicity, lenalidomide carries black box warnings for hematologic toxicity (including neutropenia and thrombocytopenia) and thromboembolism.[6] Serious side effects include thrombosis, pulmonary embolus, hepatotoxicity, and bone marrow toxicity resulting in neutropenia and thrombocytopenia. Myelosuppression is the major dose-limiting toxicity, which is not the case with thalidomide.[26]

Lenalidomide may be associated with adverse effects as second primary malignancy, severe cutaneous reactions, hypersensitivity reactions, tumor lysis syndrome, tumor flare reaction, hypothyroidism, and hyperthyroidism.[6]

Teratogenicity

[edit]

Lenalidomide is related to thalidomide, which is known to be teratogenic. Tests in monkeys suggest that lenalidomide is likewise teratogenic.[27] It cannot be prescribed for people who are pregnant or who are likely to become pregnant during therapy.[1] For this reason, the drug is only available in the United States through a restricted distribution system in conjunction with a risk evaluation and mitigation strategy. People who may become pregnant must use at least two forms of reliable contraception during treatment and for at least four weeks after discontinuing treatment with lenalidomide.[6][28]

Venous thromboembolism

[edit]

Lenalidomide, like its parent compound thalidomide, may cause venous thromboembolism, a potentially serious complication with their use. High rates of venous thromboembolism have been found in patients with multiple myeloma who received thalidomide or lenalidomide in conjunction with dexamethasone, melphalan, or doxorubicin.[29]

Stevens-Johnson syndrome

[edit]

In March 2008, the US Food and Drug Administration (FDA) included lenalidomide on a list of twenty prescription drugs under investigation for potential safety problems. The drug was investigated for possibly increasing the risk of developing Stevens–Johnson syndrome, a life-threatening skin condition.[30]

FDA ongoing safety review

[edit]

In 2011, the FDA initiated an ongoing review of clinical trials that found an increased risk of developing cancers such as acute myelogenous leukemia and B-cell lymphoma,[31] though it did not advise patients to discontinue treatment with lenalidomide.[32]

Mechanism of action

[edit]
See also: Cereblon_E3_ligase_modulator § Mechanism_of_action

Lenalidomide changes the substrate specificity of the CRL4CRBN E3 ubiquitin ligase, a complex consisting of DNA-binding protein 1 (DDB1), cullin 4a (CUL4A), regulator of cullins 1 (ROC1), and cereblon (CRBN).[9] Cereblon is the substrate adapter for the complex and is the primary molecular target of the drug.[9] Treatment with lenalidomide changes the targets of the ligase complex.[9] Subsequently, proteins IKZF1, IKZF3, and CK1α are recruited to the complex, ubiquinated, and then degraded by the proteasome.[9]

IKZF1 and IKZF3 are essential transcription factors for malignant plasma cells.[33] In particular, loss of IKZF3 then decreases the expression of interferon regulatory factor 4 (IRF4).[9] IRF4 is a master regulator of a number of cancer-promoting genes and is required for the survival of multiple myeloma.[9]

Loss of IKZF1 and IKZF3 also results in increased expression and secretion of interleukin 2 and interferon gamma, which stimulates a local immune response from T cells and NK cells.[33]

Synthesis

[edit]

The first synthesis of lenalidomide was disclosed in patents filed by Celgene.[34]

Methyl 2-methyl-3-nitrobenzoate is brominated using N-bromosuccinimide and the product is treated with 3-amino-piperidine-2,6-dione, a cyclic derivative of glutamine to form a lactam. Catalytic hydrogenation then gives lenalidomide.[35]

History

[edit]
See also: Development of analogs of thalidomide

Society and culture

[edit]
[edit]

Lenalidomide was approved for medical use in the United States in 2005.[8]

Economics

[edit]

Lenalidomide costs US$163,381 per year for the average person in the United States as of 2012.[needs update][31] Lenalidomide made almost $9.7bn for Celgene in 2018.[36]

In 2013, the UK National Institute for Health and Care Excellence (NICE) rejected lenalidomide for "use in the treatment of people with a specific type of the bone marrow disorder myelodysplastic syndrome (MDS)" in England and Scotland, arguing that Celgene "did not provide enough evidence to justify the £3,780 per month (US$5,746.73) price-tag of lenalidomide for use in the treatment of people with a specific type of the bone marrow disorder myelodysplastic syndrome (MDS)".[37]

In Australia, a 21-day course of 25 mg lenalidomide tablets costs Medicare A$2397, however the patient only pays $30 due to the Pharmaceutical Benefits Scheme.[38]

References

[edit]
  1. ^ a b "Lenalidomide (Revlimid) Use During Pregnancy". Drugs.com. 13 March 2020. Archived from the original on 9 October 2020. Retrieved 13 August 2020.
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ "LENALIDOMIDE VIATRIS (Alphapharm Pty Ltd)". Department of Health and Ages Care. Archived from the original on 13 November 2022. Retrieved 1 April 2023.
  4. ^ "Lenalidomide Sun/Lenalidomide Rbx/Lenalidomide Ran (Sun Pharma ANZ Pty Ltd)". Department of Health and Ages Care. Archived from the original on 18 March 2023. Retrieved 1 April 2023.
  5. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.
  6. ^ a b c d e "DailyMed - Revlimid- lenalidomide capsule". dailymed.nlm.nih.gov. Archived from the original on 16 February 2020. Retrieved 27 October 2019.
  7. ^ "Revlimid EPAR". European Medicines Agency. 14 June 2007. Retrieved 2 July 2024.
  8. ^ a b c d e f g h i "Lenalidomide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2016. Retrieved 27 October 2019.
  9. ^ a b c d e f g h i Fink EC, Ebert BL (November 2015). "The novel mechanism of lenalidomide activity". Blood. 126 (21): 2366–2369. doi:10.1182/blood-2015-07-567958. PMC 4653765. PMID 26438514.
  10. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  11. ^ Armoiry X, Aulagner G, Facon T (June 2008). "Lenalidomide in the treatment of multiple myeloma: a review". Journal of Clinical Pharmacy and Therapeutics. 33 (3): 219–26. doi:10.1111/j.1365-2710.2008.00920.x. PMID 18452408. S2CID 1228171.
  12. ^ a b Li S, Gill N, Lentzsch S (November 2010). "Recent advances of IMiDs in cancer therapy". Current Opinion in Oncology. 22 (6): 579–85. doi:10.1097/CCO.0b013e32833d752c. PMID 20689431. S2CID 205547603.
  13. ^ Tageja N (March 2011). "Lenalidomide - current understanding of mechanistic properties". Anti-Cancer Agents in Medicinal Chemistry. 11 (3): 315–26. doi:10.2174/187152011795347487. PMID 21426296.
  14. ^ Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. (August 2009). "Mechanism of action of lenalidomide in hematological malignancies". Journal of Hematology & Oncology. 2: 36. doi:10.1186/1756-8722-2-36. PMC 2736171. PMID 19674465.
  15. ^ Yang B, Yu RL, Chi XH, Lu XC (2013). "Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials". PLOS ONE. 8 (5): e64354. Bibcode:2013PLoSO...864354Y. doi:10.1371/journal.pone.0064354. PMC 3653900. PMID 23691202.
  16. ^ Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. (March 2012). "A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide". Blood. 119 (12): 2764–7. doi:10.1182/blood-2011-08-373514. PMID 22323483.
  17. ^ "FDA approves lenalidomide oral capsules (Revlimid) for use in combination with dexamethasone in patients with multiple myeloma". U.S. Food and Drug Administration (FDA). 29 June 2006. Archived from the original on 25 November 2011. Retrieved 15 October 2015.
  18. ^ "Lenalidomide (Revlimid)". U.S. Food and Drug Administration (FDA). 22 February 2017. Archived from the original on 13 August 2020. Retrieved 13 August 2020.
  19. ^ "REVLIMID Receives Positive Final Appraisal Determination from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales". Reuters. 23 April 2009. Archived from the original on 24 June 2009.
  20. ^ Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, et al. (Cochrane Haematology Group) (November 2019). "Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD013487. PMC 6876545. PMID 31765002.
  21. ^ List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. (February 2005). "Efficacy of lenalidomide in myelodysplastic syndromes". The New England Journal of Medicine. 352 (6): 549–57. doi:10.1056/NEJMoa041668. PMID 15703420.
  22. ^ List AF (August 2005). "Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS)". Seminars in Oncology. 32 (4 Suppl 5): S31-5. doi:10.1053/j.seminoncol.2005.06.020. PMID 16085015.
  23. ^ List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. (October 2006). "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion". The New England Journal of Medicine. 355 (14): 1456–65. doi:10.1056/NEJMoa061292. PMID 17021321.
  24. ^ "Revlimid Approved In Europe For Use In Myelodysplastic Syndromes". The MDS Beacon. Archived from the original on 21 September 2015. Retrieved 17 June 2013.
  25. ^ "Revlimid and Amyloidosis AL" (PDF). MyelomaUK. Archived from the original (PDF) on 27 September 2021. Retrieved 3 October 2020.
  26. ^ Rao KV (September 2007). "Lenalidomide in the treatment of multiple myeloma". American Journal of Health-System Pharmacy. 64 (17): 1799–807. doi:10.2146/ajhp070029. PMID 17724360.
  27. ^ "Revlimid Summary of Product Characteristics. Annex I" (PDF). European Medicines Agency. 2012. p. 6. Archived (PDF) from the original on 1 March 2014. Retrieved 16 April 2014.
  28. ^ Ness S (13 March 2014). "New Specialty Drugs". Pharmacy Times. March 2014 Mental Health. 80 (3). Archived from the original on 21 September 2015. Retrieved 5 November 2015.
  29. ^ Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, et al. (December 2006). "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer". JAMA. 296 (21): 2558–60. doi:10.1001/jama.296.21.2558-c. PMID 17148721.
  30. ^ "Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between January - March 2008". U.S. Food and Drug Administration. March 2008. Archived from the original on 19 April 2014. Retrieved 16 December 2019.
  31. ^ a b Badros AZ (May 2012). "Lenalidomide in myeloma--a high-maintenance friend". The New England Journal of Medicine. 366 (19): 1836–8. doi:10.1056/NEJMe1202819. PMID 22571206.
  32. ^ "FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies". U.S. Food and Drug Administration (FDA). April 2011. Archived from the original on 13 August 2020. Retrieved 13 August 2020.
  33. ^ a b Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machalinski B (February 2023). "Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives". Cancers. 15 (3): 963. doi:10.3390/cancers15030963. PMC 9913106. PMID 36765919.
  34. ^ US patent 5635517, George W Muller, David I Stirling, Roger S-C Chen, "Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines", issued 1997-06-03, assigned to Celgene Corp 
  35. ^ Ponomaryov Y, Krasikova V, Lebedev A, Chernyak D, Varacheva L, Chernobroviy A (2015). "Scalable and green process for the synthesis of anticancer drug lenalidomide". Chemistry of Heterocyclic Compounds. 51 (2): 133–138. doi:10.1007/s10593-015-1670-0.
  36. ^ "Top 10 Best-Selling Cancer Drugs of 2018". Genetic Engineering and Biotechnology News. 22 April 2019. Archived from the original on 23 April 2019. Retrieved 25 April 2019.
  37. ^ "Revlimid faces NICE rejection for use in rare blood cancer Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales". Pharma News. 11 July 2013. Archived from the original on 13 February 2016. Retrieved 5 November 2015.
  38. ^ Care AG, Pharmaceutical Benefits Scheme (PBS) |, Australian Government Department of Health and Aged Care, archived from the original on 31 March 2023, retrieved 31 March 2023
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lenalidomide&oldid=1239421959"